Beijing-based Sinovac Biotech’s [SVA:US] application to conduct phase III clinical trial of its inactivated COVID-19 vaccine has been approved by Bangladesh’s state medical research agency, as reported by Reuters on July 20. The trial could begin next month, involving 4,200 volunteers with half of them receiving the vaccination.
After signing a contract with the Brazil medical institution on June 13 to conduct its phase III trial in the South American country, Sinovac’s vaccine was approved by local authorities to start the trial, according to Brazil's Sao Paulo state governor. The trial would start on July 21 and is expected to be completed within 90 days. In addition, Indonesia’s state-owned company Bio Farma claimed that it will start testing Sinovac’s vaccine next month and aims to begin commercial production early next year. Currently, AstraZeneca [AZN:US] and Sinopharm’s vaccines are two other leading candidates that are already in phase III trials while Moderna’s [MRNA:US] vaccine is set to start phase III trials on July 27. According to AstraZeneca, the firm’s project may develop emergency vaccines by October with its total manufacturing capacity reaching 2bn doses per year currently.